PSMA-targeting ADC (ADCT-901)
Prostate Cancer and other PSMA-expressing Solid Tumors
Pre-INDIND-enabling activities
Key Facts
Indication
Prostate Cancer and other PSMA-expressing Solid Tumors
Phase
Pre-IND
Status
IND-enabling activities
Company
About ADC Therapeutics
ADC Therapeutics is a Switzerland-based biopharmaceutical company dedicated to transforming cancer treatment through its focused portfolio of antibody-drug conjugates. The company has achieved commercial success with ZYNLONTA®, an FDA-approved anti-CD19 ADC for specific types of large B-cell lymphoma, and is actively pursuing label expansion for this product. Concurrently, ADC Therapeutics is advancing its pipeline, including a promising PSMA-targeting ADC for solid tumors, aiming to deliver more effective and targeted therapies for patients with difficult-to-treat cancers.
View full company profile